0
September 1955, Vol 90, No. 3 >
Article | September 1955

Effect in the Newborn Infant of Reserpine Administered ante Partum FREE

IRWIN S. BUDNICK, M.D.; SANFORD LEIKIN, M.D.; LEROY E. HOECK, M.D.
[+] Author Affiliations

Submitted for publication July 15, 1955.

Reserpine supplied as Serpasil by Ciba Pharmaceutical Products, Inc.


AMA Am J Dis Child. 1955;90(3):286-289. doi:10.1001/archpedi.1955.04030010288010.
Text Size: A A A
Published online
Article
References
Comments

Reserpine is a pharmacologically active alkaloid derivative prepared from the roots of Rauwolfia serpetina, a small shrub growing wild in certain regions of India and other tropical countries.1

It is a crystalline colorless substance which is insoluble in water and moderately soluble in alcohol. Its empirical formula is C33H40O9N2.

This drug has several varied pharmacological effects.2 These consist of hypotension, bradycardia, hypothermia, increase in gastrointestinal motility, myosis, and general tranquilization.3

Because of its effect in lowering blood pressure, it is used in certain hypertensive states by itself and in combination with other drugs.* Some of the undesirable effects of this drug in the human are mental depression,5 diarrhea, and weight gain. Headache, dizziness, and nausea are also reported.1 Nasal stuffiness or "congestion" in varying percentages has been noted by several authors.† This may be relieved by topical vasoconstrictors

REFERENCES

1 +
Wilkins, R. W.; Judson, W. E.; Stone, R. W.; Hollander, W.; Huckabee, W. E., and Friedman, I. H.:  Reserpine in the Treatment of Hypertension: A Note on the Dosage and Effects , New England J. Med. 250:477-478 ( (March 18) ) 1954;.
2 +
Chopra, R. N; Gupta, J. C., and Mukherjee, B.:  The Pharmacological Action of an Alkaloid Obtained from Rauwolfia Serpentina, Benth: Preliminary Note , Indian J. M. Res. 21:261-271 ( (Oct.) ) 1933;.
3 +
Freis, E. D., and Ari, R.:  Clinical and Experimental Effects of Reserpine in Patients with Essential Hypertension , Ann. New York Acad. Sc. 59:45-53 ( (April 30) ) 1954;.
4 +
Reference deleted.
5 +
Freis, E. D.:  Mental Depression in Hypertensive Patients Treated for Long Periods with Large Doses of Reserpine , New England J. Med. 251:1006-1008 ( (Dec. 16) ) 1954;.
6 +
Hafkenschiel, J. F., and Sellers, A. M.:  Intravenous Reserpine in Patients with Essential Hypertension , Ann. New York Acad. Sc. 59:54-60, ( (April 30) ) 1954;.
7 +
Moyer, J. H.:  Cardiovascular and Renal Hemodynamic Response to Reserpine (Serpasil), and Clinical Results of Using this Agent for the Treatment of Hypertension , Ann. New York Acad. Sc. 59:82-94 ( (April 30) ) 1954;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

1 +
Wilkins, R. W.; Judson, W. E.; Stone, R. W.; Hollander, W.; Huckabee, W. E., and Friedman, I. H.:  Reserpine in the Treatment of Hypertension: A Note on the Dosage and Effects , New England J. Med. 250:477-478 ( (March 18) ) 1954;.
2 +
Chopra, R. N; Gupta, J. C., and Mukherjee, B.:  The Pharmacological Action of an Alkaloid Obtained from Rauwolfia Serpentina, Benth: Preliminary Note , Indian J. M. Res. 21:261-271 ( (Oct.) ) 1933;.
3 +
Freis, E. D., and Ari, R.:  Clinical and Experimental Effects of Reserpine in Patients with Essential Hypertension , Ann. New York Acad. Sc. 59:45-53 ( (April 30) ) 1954;.
4 +
Reference deleted.
5 +
Freis, E. D.:  Mental Depression in Hypertensive Patients Treated for Long Periods with Large Doses of Reserpine , New England J. Med. 251:1006-1008 ( (Dec. 16) ) 1954;.
6 +
Hafkenschiel, J. F., and Sellers, A. M.:  Intravenous Reserpine in Patients with Essential Hypertension , Ann. New York Acad. Sc. 59:54-60, ( (April 30) ) 1954;.
7 +
Moyer, J. H.:  Cardiovascular and Renal Hemodynamic Response to Reserpine (Serpasil), and Clinical Results of Using this Agent for the Treatment of Hypertension , Ann. New York Acad. Sc. 59:82-94 ( (April 30) ) 1954;.

Correspondence

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems